What is rivaroxaban (oral direct factor Xa inhibitor) that my female patient is taking?

What is "Roxaban"?

Your patient is taking rivaroxaban (brand name Xarelto), an oral anticoagulant medication that directly inhibits Factor Xa in the blood clotting cascade. 1

Drug Classification and Mechanism

Rivaroxaban is a direct Factor Xa inhibitor that works by selectively and reversibly blocking Factor Xa, a critical enzyme in the coagulation pathway 2. Unlike warfarin (which requires vitamin K), rivaroxaban:

• Directly inhibits both free Factor Xa and clot-bound Factor Xa 3
• Does not require cofactors like antithrombin to work 4
• Has >10,000-fold selectivity for Factor Xa over other serine proteases 5
• Blocks thrombin generation by inhibiting the prothrombinase complex 3

Common Indications

Based on FDA approval, rivaroxaban is used for 1:

• Stroke prevention in atrial fibrillation (nonvalvular)
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)
• Prevention of recurrent VTE after initial treatment
• VTE prophylaxis after hip or knee replacement surgery
• Acute coronary syndrome (in combination with antiplatelet therapy)

Standard Dosing

For atrial fibrillation 2:

• 20 mg once daily with the evening meal (if CrCl >50 mL/min)
• 15 mg once daily with the evening meal (if CrCl 30-50 mL/min)

For VTE treatment 6:

• 15 mg twice daily for 3 weeks, then
• 20 mg once daily for maintenance

Critical administration detail: Rivaroxaban must be taken with food to ensure adequate absorption 2.

Key Pharmacologic Properties

• Onset: Rapid (peak levels at 2-4 hours) 3
• Half-life: 5-9 hours in younger patients, 11-13 hours in elderly 7
• Elimination: 66% renal (36% unchanged), 28% fecal 3
• Protein binding: 92-95% 7
• Metabolism: CYP3A4 and CYP2J2 (oxidative pathways) 3

Critical Safety Considerations

Renal impairment 2:

• Avoid if CrCl <30 mL/min (or on dialysis) - no evidence for safety/efficacy
• Use caution with CrCl 30-50 mL/min (dose reduction required)

Contraindications 7:

• Active pathological bleeding
• Severe renal impairment (CrCl <30 mL/min)
• Pregnancy and breastfeeding 8
• Severe hepatic impairment

Drug interactions 1:

• Avoid combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir)
• Concomitant NSAIDs/aspirin increases bleeding risk
• Clopidogrel doubles bleeding time when combined

Bleeding Management

No specific antidote was available until recently 3. Current reversal options 9:

• Andexanet alfa (FDA-approved 2019): Recombinant Factor Xa variant that binds rivaroxaban
  • Reduces anti-Xa activity by 92% within 4 hours
  • Indicated for life-threatening bleeding
• Prothrombin complex concentrates (PCCs): May bypass anticoagulant effects
• Hemodialysis: Not effective (high protein binding limits removal)

For minor bleeding: Stop drug, provide supportive care. Rivaroxaban levels drop to 25% by 24 hours if CrCl >50 mL/min 3.

Practical Monitoring

No routine coagulation monitoring required 10, but if needed:

• PT/INR prolongation correlates with drug levels
• Anti-Factor Xa assay can measure drug concentration
• aPTT is less sensitive but shows some prolongation

Common Pitfalls

1. Forgetting food requirement: Absorption significantly reduced without food, especially for 15-20 mg doses
2. Inappropriate use in severe renal impairment: High bleeding risk with inadequate clearance
3. Premature discontinuation: Increases stroke/VTE risk - ensure bridging plan if stopping
4. Combining with multiple antithrombotics: Additive bleeding risk with aspirin, NSAIDs, or clopidogrel 1